80.7% sensitivity_at_97_9_percent_specificity
cfMethyl-Seq all-stage cancer detection reported endpoint
- Tested configuration
- cfMethyl-Seq stacked ensemble (2022)
- Protocol
- cfMethyl-Seq random-split four-cancer detection
- Dataset
- cfMethyl-Seq 408 QC-passing plasma samples
- Procedure
- amp-protocol-cfmethyl-randomsplit-detection
- Evaluation
- cfMethyl-Seq all-stage cancer detection
- Coverage
- scored: unreported; eligible: unreported
- Uncertainty
- 95% CI 68.6%–90.7%
- Evidence
- Author-reported evaluation · source checkedcfMethyl-Seq cancer detection primary paper · PMC9522828 XML Par17, Results Cancer detection, Fig3a; split Par16; configuration Par37
A source-checked result verifies the numerical transcription, not every model or protocol detail. Evaluation metadata: source checked. Source checked does not mean independently reproduced.
Reproduction
- Split
- 10 repeated random 75:25 train/test splits
- Adaptation
- Not reported
- Scoring implementation
- Not reported
No execution recipe has been verified for this exact configuration and evaluation. A benchmark's general instructions may use different inputs, splits or model settings.
Reproducing this published result requires matching its model configuration, data, split and scorer. Source checking or a successful smoke test does not establish score reproduction.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
1 evidence row matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| Reported result 80.7 Individual claims | cfMethyl-Seq cancer detection primary paper PMC9522828 XML Par17, Results Cancer detection, Fig3a; split Par16; configuration Par37 Version: 2022 version of record, corrected competing-interest disclosure in 2024 | source checked automated source review · 2026-10-07T12:28:51.639798+00:00 author reported Audit detailsDirect primary-text and OOXML cell inspection. Candidate curation pending parent review; no execution, reproduction or qualified human scientific review. Field: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
View linked audit checks and correction history
Release 2026-10-07-1448159e6a81 · Record review: source checked
1 source records and release history
- cfMethyl-Seq cancer detection primary paper · Original source · 2022 version of record, corrected competing-interest disclosure in 2024
Technical metadata and extraction receipts
Stable ID: amp-result-cfmethyl-allstage-sensitivity
- areas
- dna-genomes
- contexts
- clinical_research
- metric
- sensitivity_at_97_9_percent_specificity
- metric direction
- higher
- missing metadata
- integer test denominators: Not inferred from rounded split fractions; metric implementation: Author-reported sensitivity, no executable metric version extracted; seed: Unreported
- numeric value
- 80.7
- printed value
- 80.7
- review
- method: automated_source_review; notes: Direct primary-text and OOXML cell inspection. Candidate curation pending parent review; no execution, reproduction or qualified human scientific review.; reviewed at: 2026-10-07T12:28:51.639798+00:00; reviewer: Codex AMP methylation/CNV/operations evidence worker
- source locator
- PMC9522828 XML Par17, Results Cancer detection, Fig3a; split Par16; configuration Par37
- uncertainty
- 95% CI 68.6%–90.7%
- unit
- percent
Related records
- evaluation: cfMethyl-Seq all-stage cancer detection